Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis
The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 23, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other...
ImmVira Presents Clinical Data from Three Bladder Cancer Studies at ESMO 2026
SUZHOU, China, Oct. 23, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that updated clinical data from three bladder cancer studies of its lead oncolytic immunotherapy candidate, MVR-T3011, will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress. These presentations covered three key patient populations: 1) BCG-unresponsive high-risk...
After Repeated IVF Failures, What Comes Next? Taiwan Fertility Specialists to Share New Perspectives on IVF Treatment in South Korea
TAIPEI, Oct. 23, 2026 /PRNewswire/ -- As marriage and childbearing are increasingly delayed, fertility planning and infertility treatment have become important considerations for many families. For couples who have experienced multiple unsuccessful IVF cycles or recurrent pregnancy loss, reviewing previous treatment outcomes and seeking a second medical opinion may help inform their next steps. Ms. R, a 38-year-old...
Johnson & Johnson Deepens its Long-Term Commitment to Hong Kong Through OASES Strategic Enterprise Collaboration
Building on more than five decades in Hong Kong, Johnson & Johnson is committed to advancing better health through science, innovation and collaboration for patients and communities in Hong Kong. The partnership will help strengthen clinical research, develop future healthcare talent and support Hong Kong's ambition to become a leading international...
Tairex Launches Multi-Agent AI System to Transform Clinical Collaboration and Decision Support
BEIJING, Oct. 22, 2026 /PRNewswire/ -- On 21 October, Tairex, an AI healthcare technology company incubated by the Institute for AI Industry Research (AIR) at Tsinghua University, unveiled the Multidisciplinary Human-Agent Collaboration (MHAC) Ecosystem for Agent Hospital, designed to enable specialized AI agents to work alongside physicians on clinical cases. While AI systems have become increasingly capable of...
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to receive $45 million in upfront and near-term payments, as part of a total deal value of up to $1.1 billion, plus royalties. FLORENCE, Italy and GAITHERSBURG, Md., Oct. 22, 2026...
New hair transplant review challenges fixed donor limits
Dr. Umar and colleagues outline how individualized assessment may reveal additional graft options while identifying areas to avoid MANHATTAN BEACH, Calif., Oct. 22, 2026 /PRNewswire/ -- Dr. U Hair and Skin Clinic in the Los Angeles area reports that a new clinical review led by Sanusi Umar, MD, challenges reliance on...
Vespexx Recognized as Finalist for the Digital Health Hub Foundation Digital Health & AI Awards 2026 at HLTH
SEOUL, South Korea, Oct. 22, 2026 /PRNewswire/ -- Vespexx Inc., an AI-driven femtech company, today announced it has been named a Finalist for the Digital Health Hub Foundation's Digital Health & AI Awards 2026, held at HLTH. Competing in the Rising Star track under the Women's & Family Health category, Vespexx advanced from the Quarterfinalist stage announced earlier...
ZEISS announces availability of CT LUCIA 621P in Japan, expanding its broad ZEISS Cataract Workflow
The ZEISS CT LUCIA 621P monofocal intraocular lens (IOL) is added to the ZEISS Cataract Workflow in the Japanese market, supporting good visual outcomes for patients. JENA, Germany and TOKYO, Oct. 22, 2026 /PRNewswire/ -- ZEISS Medical Technology announced today the commercial availability of the CT LUCIA® 621P monofocal IOL from ZEISS...
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
TAIZHOU, China, Oct. 22, 2026 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the "Company"), today announced that it will effect a share consolidation of its Class A ordinary shares, no par value per share, at a ratio of 1-for-100, effective on October 26, 2026 (the "Share Consolidation"). The Company's Class A ordinary shares are expected to begin...
